Clinical trial NCT01497197: A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique
Official title: A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Infertility
Fertility
Follicle Stimulating Hormone Deficiency
Keywords: Reproduction Techniques
Reproductive Medicine
Assisted Reproductive Technics
Pregnancy Rate
Ovulation Induction
Ovarian Stimulation
Oocytes
Implantation
Lead sponsor: Merck KGaA, Darmstadt, Germany
Sponsor class: INDUSTRY
Collaborators: name: Merck Serono Middle East FZ LLC
First posted: 2011-12-22
Enrollment: 174
Sex: FEMALE
Minimum age (years): 36
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a phase IIIb, interventional, multicenter, multinational, randomised, open-label, comparative trial which primary objective is to generate data on the ovarian stimulation profile obtained when Luveris® is started either on Day 1 or Day 6 in women in advanced reproductive age (36-42) undergoing Assisted Reproductive Technique (ART).

Detailed description: The subjects who complete the screening assessments and fulfil all the eligibility criteria will start down-regulation treatment on day 21-22 of the cycle.

Down-regulation treatment must start within 2 months following the screening visit. The routine long luteal phase protocol for Gonadotrophin-releasing hormone (GnRH) agonist treatment will be followed.

Once down-regulation has been confirmed, a pregnancy test will be performed within 1 week prior to start of Recombinant human follicle stimulating hormone (r-hFSH) treatment to rule out any pre-existing pregnancy. If the result is negative, the subject will be randomly assigned to one of the two treatment arms of the trial:

* GONAL-f® (Liquid Pen; 300 IU of per day) stimulation day 1-5 then followed by Luveris® (vial/powder, 150 IU per day) from stimulation Day 1 and until required r-hCG level is met. The dose can be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
* GONAL-f® (Liquid Pen; 300 IU per day) stimulation Day 1-5 then add Luveris® (vial/powder, 150 IU per day) from stimulation Day 6 and until required recombinant Human chorionic gonadotrophin (r-hCG) level is met. The dose can be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.

Randomization across the two treatment arms will be kept balanced in a 1:1 ratio. Subjects will be provided with a subject diary (including r-hCG and Crinone® administration and safety information) to record daily dosing information for GONAL-f® and Luveris®.

Follicular development will be monitored according to the center's standard practice by US and/or Oestradiol (E2) levels, until the protocol r-hCG requirement is met (i.e., at least 1 follicle greater or equal to 18 mm and 2 follicles greater or equal to 16 millimeter \[mm\]). After this, a single injection of 250 microgram (mcg) of r-hCG (Ovidrel®/Ovitrelle®), will be administered in order to induce final oocyte maturation.

At a time of 34-38 hours after r-hCG administration, oocytes will be recovered vaginally under US monitoring. Oocytes will then be fertilized in vitro and embryos replaced 2-3 days after oocyte recovery. Ovum pick up (OPU), in vitro fertilization (IVF), Embryo Transfer (ET) and luteal support will be performed as per center's standard practice. In addition, Crinone® 8% (progesterone gel) will be administered once daily.

A post-treatment safety visit will be performed for all subjects who received r-hCG (pregnant and non-pregnant) on post r-hCG Day 15-20. For subjects who have withdrawn from treatment (i.e. after starting Luveris® or GONAL f® but before r-hCG is given) this visit will take place 20-30 days after their first Luveris® or GONAL-f® treatment injection (excluding pregnancy testing).

Eligibility criteria: Inclusion Criteria:

* Should be a female subject justifying an In Vitro Fertilization/Embryo transfer (IVF)/ET treatment
* Should be between 36th and 42nd birthday (both included) at the time of the randomization visit
* Have early follicular phase (day 2-4) serum level of basal FSH \<= 12 IU/L measured in the center's local laboratory during the screening period (i.e. within 2 months prior to down regulation start)
* Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length
* Presence of both ovaries
* Normal uterine cavity, which in the investigator's opinion is compatible with Pregnancy
* Have a negative cervical Papanicolaou (PAP or smear) test within the last 6 months prior to randomization
* Have at least one wash-out cycle (defined as \>=30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting GnRH agonist therapy
* Be willing and able to comply with the protocol for the duration of the trial
* Have given written informed consent, prior to any trial-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care
* Have a male partner with semen analysis within the past 6 months prior to randomization considered adequate to proceed with regular insemination or intra-cytoplasmic sperm injection (ICSI) according to the center's standard practice

Exclusion Criteria:

* Had 2 (or more) previous ART cycles with a poor response to gonadotrophin stimulation defined as 6 (or less) mature follicles and/or 4 (or less) oocytes collected in any previous IVF cycle or previous cycles with a hyper response defined as 25 (or more) oocytes retrieved
* Any medical condition, which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Merck Serono's Medical responsible
* Had previous severe ovarian hyperstimulation syndrome (OHSS)
* Polycystic ovary syndrome (PCOS; Rotterdam criteria) to reduce the risk of the occurrence of OHSS
* Presence of endometriosis requiring treatment
* Uterine myoma requiring treatment
* Any contraindication to being pregnant and/or carrying a pregnancy to term
* Extra-uterine pregnancy within the last 3 months prior to screening
* History of 3 or more miscarriages (early or late miscarriages) due to any cause
* Tumours of the hypothalamus and pituitary gland
* Ovarian enlargement or cyst of unknown etiology
* Ovarian, uterine or mammary cancer
* A clinically significant systemic disease
* Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus in the trial subject or her male partner
* Abnormal gynecological bleeding of undetermined origin
* Known allergy or hypersensitivity to human gonadotrophin preparations
* Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years prior to the screening visit
* Entered previously into this trial or simultaneous participation in another clinical trial
* Pregnancy and lactation period
* Participation in another clinical trial within the past 30 days

Primary outcomes:
measure: Total Number of Oocytes Retrieved Per Subject Following Ovarian Stimulation
timeFrame: 34-38 hours post r-hCG administration
Secondary outcomes:
measure: Total Dose and Mean Daily Dose of Follicle Stimulating Hormone (FSH)
timeFrame: Screening
measure: Total Number of Stimulation Treatment Days
timeFrame: 6 days post stimulation (Number of stimulation days+6 days)
measure: Implantation Rate
timeFrame: 35-42 days post r-hCG administration
measure: Number of Fetal Sacs With Activity
timeFrame: 35-42 days post r-hCG administration
measure: Number of Fetal Sacs With Detectable Heart Beats
timeFrame: 35-42 days post r-hCG administration
measure: Total Pregnancy Rate and Clinical Pregnancy Rate
timeFrame: 35-42 days post r-hCG administration
measure: Cycle Cancellation Rate Prior to r-hCG
timeFrame: Up to 85 days
measure: Number of Subjects With Biochemical Pregnancies
timeFrame: 35 to 42 days post r-hCG administration
measure: Number of Subjects With Multiple Pregnancies
timeFrame: 35 to 42 days post r-hCG administration
measure: Number of Subjects With Any Adverse Events (AEs), Serious AEs, AEs Leading to Death, and AEs Leading to Discontinuation
timeFrame: Baseline up to 15-20 days post r-hCG administration
Other outcomes:
Locations:
city: Dubai
country: United Arab Emirates
facility: Merck Serono Research Site
Study officials:
affiliation: Merck Serono Middle East FZ LLC
name: Medical Director
role: STUDY_DIRECTOR
References: